Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands

Denise Laura Wootten, Emilia Elizabeth Savage, Francis S Willard, Ana B Bueno, Kyle W Sloop, Arthur Christopoulos, Patrick Sexton

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis. Despite the availability of peptide-based GLP-1R drugs for treatment of this disease, there is great interest in developing small molecules that can be administered orally. The GLP-1R system is complex, with multiple endogenous and clinically used peptide ligands that exhibit different signaling biases at this receptor. This study revealed that small molecule ligands acting at this receptor are differentially biased to peptide ligands and also from each other with respect to the signaling pathways that they activate. Furthermore, allosteric small molecule ligands were also able to induce bias in signaling mediated by orthosteric ligands. This was dependent on both the orthosteric and allosteric ligand as no two allosteric-orthosteric ligand pairs could induce the same signaling profile. We highlight the need to profile compounds across multiple signaling pathways and in combination with multiple orthosteric ligands in systems such as the GLP-1R where more than one endogenous ligand exists. In the context of pleiotropical coupling of receptors and the interplay of multiple pathways leading to physiologic responses, profiling of small molecules in this manner may lead to a better understanding of the physiologic consequences of biased signaling at this receptor. This could enable the design and development of improved therapeutics that have the ability to fine-tune receptor signaling, leading to beneficial therapeutic outcomes while reducing side effect profiles.
Original languageEnglish
Pages (from-to)822 - 834
Number of pages13
JournalMolecular Pharmacology
Volume83
Issue number4
DOIs
Publication statusPublished - 2013

Cite this

Wootten, Denise Laura ; Savage, Emilia Elizabeth ; Willard, Francis S ; Bueno, Ana B ; Sloop, Kyle W ; Christopoulos, Arthur ; Sexton, Patrick. / Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. In: Molecular Pharmacology. 2013 ; Vol. 83, No. 4. pp. 822 - 834.
@article{b44204ba9f9a4e0d814af177ff343d80,
title = "Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis. Despite the availability of peptide-based GLP-1R drugs for treatment of this disease, there is great interest in developing small molecules that can be administered orally. The GLP-1R system is complex, with multiple endogenous and clinically used peptide ligands that exhibit different signaling biases at this receptor. This study revealed that small molecule ligands acting at this receptor are differentially biased to peptide ligands and also from each other with respect to the signaling pathways that they activate. Furthermore, allosteric small molecule ligands were also able to induce bias in signaling mediated by orthosteric ligands. This was dependent on both the orthosteric and allosteric ligand as no two allosteric-orthosteric ligand pairs could induce the same signaling profile. We highlight the need to profile compounds across multiple signaling pathways and in combination with multiple orthosteric ligands in systems such as the GLP-1R where more than one endogenous ligand exists. In the context of pleiotropical coupling of receptors and the interplay of multiple pathways leading to physiologic responses, profiling of small molecules in this manner may lead to a better understanding of the physiologic consequences of biased signaling at this receptor. This could enable the design and development of improved therapeutics that have the ability to fine-tune receptor signaling, leading to beneficial therapeutic outcomes while reducing side effect profiles.",
author = "Wootten, {Denise Laura} and Savage, {Emilia Elizabeth} and Willard, {Francis S} and Bueno, {Ana B} and Sloop, {Kyle W} and Arthur Christopoulos and Patrick Sexton",
year = "2013",
doi = "10.1124/mol.112.084525",
language = "English",
volume = "83",
pages = "822 -- 834",
journal = "Molecular Pharmacology",
issn = "1521-0111",
publisher = "ACS Books",
number = "4",

}

Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. / Wootten, Denise Laura; Savage, Emilia Elizabeth; Willard, Francis S; Bueno, Ana B; Sloop, Kyle W; Christopoulos, Arthur; Sexton, Patrick.

In: Molecular Pharmacology, Vol. 83, No. 4, 2013, p. 822 - 834.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands

AU - Wootten, Denise Laura

AU - Savage, Emilia Elizabeth

AU - Willard, Francis S

AU - Bueno, Ana B

AU - Sloop, Kyle W

AU - Christopoulos, Arthur

AU - Sexton, Patrick

PY - 2013

Y1 - 2013

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis. Despite the availability of peptide-based GLP-1R drugs for treatment of this disease, there is great interest in developing small molecules that can be administered orally. The GLP-1R system is complex, with multiple endogenous and clinically used peptide ligands that exhibit different signaling biases at this receptor. This study revealed that small molecule ligands acting at this receptor are differentially biased to peptide ligands and also from each other with respect to the signaling pathways that they activate. Furthermore, allosteric small molecule ligands were also able to induce bias in signaling mediated by orthosteric ligands. This was dependent on both the orthosteric and allosteric ligand as no two allosteric-orthosteric ligand pairs could induce the same signaling profile. We highlight the need to profile compounds across multiple signaling pathways and in combination with multiple orthosteric ligands in systems such as the GLP-1R where more than one endogenous ligand exists. In the context of pleiotropical coupling of receptors and the interplay of multiple pathways leading to physiologic responses, profiling of small molecules in this manner may lead to a better understanding of the physiologic consequences of biased signaling at this receptor. This could enable the design and development of improved therapeutics that have the ability to fine-tune receptor signaling, leading to beneficial therapeutic outcomes while reducing side effect profiles.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis. Despite the availability of peptide-based GLP-1R drugs for treatment of this disease, there is great interest in developing small molecules that can be administered orally. The GLP-1R system is complex, with multiple endogenous and clinically used peptide ligands that exhibit different signaling biases at this receptor. This study revealed that small molecule ligands acting at this receptor are differentially biased to peptide ligands and also from each other with respect to the signaling pathways that they activate. Furthermore, allosteric small molecule ligands were also able to induce bias in signaling mediated by orthosteric ligands. This was dependent on both the orthosteric and allosteric ligand as no two allosteric-orthosteric ligand pairs could induce the same signaling profile. We highlight the need to profile compounds across multiple signaling pathways and in combination with multiple orthosteric ligands in systems such as the GLP-1R where more than one endogenous ligand exists. In the context of pleiotropical coupling of receptors and the interplay of multiple pathways leading to physiologic responses, profiling of small molecules in this manner may lead to a better understanding of the physiologic consequences of biased signaling at this receptor. This could enable the design and development of improved therapeutics that have the ability to fine-tune receptor signaling, leading to beneficial therapeutic outcomes while reducing side effect profiles.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23348499

U2 - 10.1124/mol.112.084525

DO - 10.1124/mol.112.084525

M3 - Article

VL - 83

SP - 822

EP - 834

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 1521-0111

IS - 4

ER -